|1.||Satoh, Hiroshi: 1 article (01/2013)|
|2.||Iida, Hiroyuki: 1 article (01/2004)|
|3.||Abe, Mitsuhiro: 1 article (01/2004)|
|4.||Inoue, Shigeharu: 1 article (01/2004)|
|5.||Okabe, Susumu: 1 article (01/2004)|
|6.||Yuda, Yasukatu: 1 article (01/2004)|
|7.||Tanaka, Junko: 1 article (01/2004)|
|1.||Duodenal Ulcer (Curling's Ulcer)
01/01/2004 - "The development of duodenal ulcers caused by mepirizole and systeamine was also potently inhibited by ME3407 at an oral dose of 0.1-30 mg/kg. However, when given at 30 mg/kg intraduodenally, subcutaneously or intravenously, ME3407 did not inhibit these acutely induced gastric elosion and acid output. "
09/01/1987 - "The decreased prostaglandin formation, although not causing duodenal ulcers, may lower the resistance of duodenal mucosa to the hyperacidity induced by mepirizole. "
09/01/1987 - "Prostaglandin deficiency by itself is not the cause of mepirizole-induced duodenal ulcers in rats."
12/01/1986 - "twice (9.5 hr apart), significantly inhibited the development of duodenal ulcers induced by mepirizole (200 mg/kg, s.c.), but did not inhibit gastric lesions developed simultaneously. "
09/01/1986 - "Although the ulcerogenicity of mepirizole was weak at 7 h, severe duodenal ulcers developed at 24 h and after the repeated administration. "
03/01/1992 - "In addition, the agent significantly protected the duodenal mucosa against mepirizole-induced ulcers. "
01/01/1980 - "The addition of 200 mg/kg of mepirizole reduced the ulcer index from 8.1 to 4.7 in the corpus and from 4 to 0.5 in the pyloric antrum. "
08/01/1998 - "Oral administration of mepirizole (200 mg/kg) resulted in ulcer lesions in the proximal duodenum. "
01/01/1983 - "Mepirizole-induced duodenal ulcers appear to be a useful model for the study of ulcer healing and for screening of antiulcer drugs."
01/01/1999 - "In contrast, L-365, 260 (30 mg/kg) tended to reduce the severity of mepirizole-induced duodenal ulcers, with a slight inhibition of acid secretion, but it caused no influence on the healing response of these ulcers. "
|3.||Stomach Ulcer (Gastric Ulcer)
09/01/1987 - "Indomethacin (10 mg/kg subcutaneously) produced gastric ulcers, whereas mepirizole (100 mg/kg subcutaneously) produced exclusively duodenal ulcers. "
09/01/1987 - "The purpose of these studies was to determine the role played by endogenous prostaglandins in the development of gastric ulcers produced by indomethacin, and of duodenal ulcers produced by mepirizole in rats. "
11/01/1990 - "FRG-8701 showed antiulcer activity against stress and indomethacin gastric ulcer and mepirizole duodenal ulcer. "
09/01/1987 - "Oral administration of 16,16-dimethyl PGE2, given at nonantisecretory doses (0.5-5 micrograms/kg), prevented formation of indomethacin-induced gastric ulcers, whereas antisecretory doses were required to prevent formation of mepirizole-induced duodenal ulcers. "
06/01/1989 - "HWA 285 (10-50 mg/kg, p.o.) inhibited restraint and water-immersion-induced stress, ulcers, indometacin- and absolute ethanol-induced gastric ulcers and mepirizole-induced duodenal ulcers in rats in a dose-dependent manner. "
05/01/1985 - "These results suggest that the site of action of the basic nonsteroidal anti-inflammatory drugs such as tiaramide.HCl and mepirizole is not the inflamed site, and certain systemic effects may contribute to the anti-edema effects."
05/01/1985 - "Locally administered mepirizole, tiaramide.HCl and aminopyrine, the basic nonsteroidal anti-inflammatory drugs, didn't show any suppression against the edema formation. "
12/01/1985 - "On the other hand, salicylic acid, mepirizole and tiaramide X HCl inhibited the hind paw edema induced by carrageenin + PGE2 in rats. "
09/01/1978 - "In the carrageenin-induced edema test in rats, the anti-inflammatory activity of SL-573 was 1.6 times as potent as those of phenylbutazone (PB) and ibuprofen (IP), 3.3 times as potent as that of mefenamic acid (MF) and 6.7 times as potent as that of mepirizole (MP). "
03/01/1979 - "M73101 showed a marked inhibitory effect against rat paw edema induced by various phlogistic agents (carrageenin, dextran, histamine, serotonin and bradykinin) and the activities were equal to or more potent than those of aminopyrine, mepirizole and tiaramide HCl. "
11/01/1986 - "significantly protected the duodenal mucosa against mepirizole-induced damage for up to 6 hr. Gastric acid secretion in acute fistula preparations was significantly reduced 1 hr after administration of mepirizole (60 and 200 mg/kg). "
06/01/1983 - "Mepirizole at 200 mg/kg given intraduodenally significantly reduced the volume of gastric juice but increased the acidity and pepsin activity in both pylorus-ligated and acute fistula rats. "
03/01/1999 - "Pantoprazole (0.3-3 mg/kg, p.o.) as well as omeprazole (1-10 mg/kg, p.o.) and lansoprazole (1-10 mg/kg, p.o.) dose-dependently decreased both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats, and the effects of pantoprazole were more potent than those of omeprazole and lansoprazole, the ED50 values for the stimulated acid secretion being 0.8, 2.0 and 1.2 mg/kg, respectively. "
|3.||Aspirin (Acetylsalicylic Acid)
|5.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
|6.||Ethanol (Ethyl Alcohol)
|7.||Histamine (Histamine Dihydrochloride)